New York State Common Retirement Fund Has $55.61 Million Position in argenx SE (NASDAQ:ARGX)

New York State Common Retirement Fund boosted its stake in shares of argenx SE (NASDAQ:ARGX) by 15.0% in the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 146,168 shares of the company’s stock after acquiring an additional 19,032 shares during the quarter. New York State Common Retirement Fund’s holdings in argenx were worth $55,607,000 as of its most recent SEC filing.

Several other hedge funds have also recently bought and sold shares of the stock. Parkside Financial Bank & Trust bought a new position in shares of argenx in the third quarter valued at about $28,000. FNY Investment Advisers LLC bought a new position in shares of argenx in the fourth quarter valued at about $38,000. Nkcfo LLC raised its holdings in shares of argenx by 22.1% in the third quarter. Nkcfo LLC now owns 116 shares of the company’s stock valued at $57,000 after buying an additional 21 shares during the last quarter. CWM LLC raised its holdings in shares of argenx by 29.4% in the third quarter. CWM LLC now owns 207 shares of the company’s stock valued at $102,000 after buying an additional 47 shares during the last quarter. Finally, Toronto Dominion Bank raised its holdings in shares of argenx by 174.2% in the third quarter. Toronto Dominion Bank now owns 266 shares of the company’s stock valued at $131,000 after buying an additional 169 shares during the last quarter. 60.32% of the stock is currently owned by institutional investors and hedge funds.

Analyst Ratings Changes

ARGX has been the subject of a number of research analyst reports. Wells Fargo & Company boosted their price objective on argenx from $472.00 to $478.00 and gave the stock an “overweight” rating in a report on Tuesday, February 20th. JMP Securities restated a “market outperform” rating and set a $471.00 target price on shares of argenx in a research report on Friday, March 22nd. Truist Financial boosted their target price on argenx from $370.00 to $440.00 and gave the stock a “buy” rating in a research report on Tuesday, March 5th. Robert W. Baird decreased their target price on argenx from $505.00 to $490.00 and set an “outperform” rating for the company in a research report on Friday, March 1st. Finally, Scotiabank boosted their target price on argenx from $402.00 to $408.00 and gave the stock a “sector perform” rating in a research report on Tuesday, March 26th. One analyst has rated the stock with a sell rating, five have assigned a hold rating, fourteen have issued a buy rating and one has assigned a strong buy rating to the stock. According to data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and a consensus target price of $528.16.

argenx Stock Up 1.7 %

NASDAQ:ARGX opened at $375.08 on Wednesday. The business has a 50 day moving average price of $386.95 and a two-hundred day moving average price of $419.33. argenx SE has a twelve month low of $327.73 and a twelve month high of $550.76.

argenx (NASDAQ:ARGX) last released its quarterly earnings data on Thursday, February 29th. The company reported ($1.68) earnings per share for the quarter, missing the consensus estimate of ($1.23) by ($0.45). The business had revenue of $417.84 million during the quarter, compared to analyst estimates of $378.60 million. argenx had a negative net margin of 23.26% and a negative return on equity of 16.97%. During the same period last year, the business earned ($0.70) earnings per share. On average, research analysts expect that argenx SE will post -2.1 EPS for the current year.

argenx Company Profile

argenx SE, a biotechnology company, engages in the developing of various therapies for the treatment of autoimmune diseases in the United States, Japan, Europe, Middle East, Africa, and China. Its lead product candidate is efgartigimod for the treatment of patients with myasthenia gravis, immune thrombocytopenia, pemphigus vulgaris, generalized myasthenia gravis, chronic inflammatory demyelinating polyneuropathy, thyroid eye disease, bullous pemphigoid, myositis, primary sjögren's syndrome, post-covid postural orthostatic tachycardia syndrome, membranous nephropathy, lupus nephropathy, anca-associated vasculitis, and antibody mediated rejection; ENHANZE SC; Empasiprubart for multifocal motor neuropath, delayed graft function, and dermatomyositis; and ARGX-119 for congenital myasthenic syndrome and amyotrophic lateral sclerosis.